Daiichi Sankyo Company, Limited
4568
Clasificación en acciones
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Precio por acción
$18.01
Capitalización bursátil
$32.77B
Cambio (1 día)
0.14%
Cambio (1 año)
-30.22%
País
JP
Comercio Daiichi Sankyo Company, Limited (4568)
Categoría
Healthcare
Historial de rendimiento por dividendo de Daiichi Sankyo Company, Limited (4568)
Rendimiento por dividendo (TTM) de Daiichi Sankyo Company, Limited (símbolo bursátil: 4568) al 2025-03-31: 1.72%
Rendimiento promedio por dividendo de los últimos 5 años: 0.97%
Rendimiento promedio por dividendo de los últimos 5 años: 0.97%
Historial de rendimiento por dividendo de Daiichi Sankyo Company, Limited (4568) desde 2001 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
| Año | Rendimiento por dividendo | Cambiar |
|---|---|---|
| 2026 (TTM) | 3.14% | 82.56% |
| 2025 | 1.72% | 129.33% |
| 2024 | 0.75% | 27.12% |
| 2023 | 0.59% | -41.58% |
| 2022 | 1.01% | 29.49% |
| 2021 | 0.78% | -17.02% |
| 2020 | 0.94% | -25.98% |
| 2019 | 1.27% | -36.18% |
| 2018 | 1.99% | -23.75% |
| 2017 | 2.61% | -7.12% |
| 2016 | 2.81% | -10.79% |
| 2015 | 3.15% | -8.70% |
| 2014 | 3.45% | -0.29% |
| 2013 | 3.46% | -13.07% |
| 2012 | 3.98% | 6.42% |
| 2011 | 3.74% | -6.50% |
| 2010 | 4.00% | -12.47% |
| 2009 | 4.57% | 106.79% |
| 2008 | 2.21% | 45.39% |
| 2007 | 1.52% | 72.73% |
| 2006 | 0.88% | -45.00% |
| 2005 | 1.60% | 1.91% |
| 2004 | 1.57% | -0.63% |
| 2003 | 1.58% | 690.00% |
| 2002 | 0.20% | -76.47% |
| 2001 | 0.85% | 0.00% |
Rendimientos por dividendo (TTM) de empresas similares o competidoras
| Empresa | Rendimiento por dividendo | País |
|---|---|---|
| 0.51% |
US
|
|
| 2.01% |
US
|
|
| 2.43% |
US
|
|
| 2.23% |
US
|
|
| 2.50% |
CH
|
